Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard S&P 500 Growth Index Fund ETF (VOOG) vs Viatris Inc (VTRS) Price & Performance

Vanguard S&P 500 Growth Index Fund ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Vanguard S&P 500 Growth Index Fund ETF vs Viatris Inc — how do they compare? Vanguard S&P 500 Growth Index Fund ETF trades at $87.29 (market cap $27.10B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard S&P 500 Growth Index Fund ETF for 54 Days and Viatris Inc for 57 Days on average.

VOOGVTRS
Market Cap
$27.10B$20.03B
Volume
1,178,31214,109,977
Sector
Broad Market / FactorHealth
52-Week High
$87.81$18.27
52-Week Low
$65.32$9.74
Typical Hold Time
54 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard S&P 500 Growth Index Fund ETF

VOOG trades at $87.29, down 0.46% on the day, maintaining a bullish technical stance with strong moving average support. The ETF holds 148 large-cap growth stocks from the S&P 500, with significant technology sector exposure. Recent institutional buying activity from firms like Integrated Wealth Concepts and NewEdge Advisors signals confidence in the growth-focused strategy. Technical indicators show bullish momentum with key support at $85 and resistance at $88.

VOOG's long-term growth potential remains compelling with 400% returns over the past decade and 14% gains year-to-date. The ETF's low 0.07% expense ratio and focus on high-performing growth stocks provide cost-effective exposure to market leaders. However, concentration in technology stocks and sensitivity to interest rate changes present risks. The current neutral oscillator readings suggest potential for consolidation near recent highs.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VOOG
5% Buy95% Sell
Avg holding period · 54 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Vanguard S&P 500 Growth Index Fund ETF

VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.

Read more on VOOG →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →